Guest guest Posted September 8, 2007 Report Share Posted September 8, 2007 Bioport, a.k.a. Emergent Biosolutions, began selling shares to the public last November. Its price peaked in January at $17.75 per share. Since then it has spiralled down, closing at $8.45 yesterday. On the one hand, this is a reflection of the market's lack of confidence in Bioport/EBS. However, this loss of over $250 million in market capitalization over 8 months can be viewed another way by the company's major shareholders, of whom Fuad El-Hibri is by far the largest owner. It can be seen as an amount that could be gotten back--with potentially even higher share prices--if the company can convince the government to stockpile even more anthrax vaccine for civilians, and require it for larger number of soldiers; for instance, even for those who never deploy. Thus a gain of $250 million or more rests on convincing the government to buy more vaccine. For such a gain (and to prevent a loss of the rest of the company's market value), Bioport is prepared to spend lavishly on lobbying, politically-connected employees, and whatever it takes to sell their one product. Stay tuned as millions more are spent to influence procurement of Biothrax. MN Meryl Nass, MD Mount Desert Island Hospital Bar Harbor, Maine 04609 207 288-5081 ext. 220 http://anthraxvaccine.blogspot.com http://www.anthraxvaccine.org Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.